Navigation Links
NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
Date:4/28/2011

ass="discStyle" type="disc">
  • Patents relating to capsaicin prodrugs entitled, "TRPV1 Agonist Compounds and Methods for Making and Using the Same," have issued in the United Stated and Mexico.

    • Patents relating to capsaicin oils entitled, "Oils of Capsaicinoids and Methods of Making and Using the Same," have issued in the United States, throughout Europe and Eurasia.

    • With respect to the skin cleansing gel, which is a component of the Qutenza treatment kit and is used to remove residual capsaicin from the skin after a Qutenza treatment, patents entitled, "Compositions and Kits for the Removal of Irritating Compounds from Bodily Surfaces," have issued in Eurasia and Japan.  

    • A patent relating to a capsaicin patch including specific penetration enhancers entitled, "Device for Delivery of TRPV1 Agonists," has issued in South Africa.

    About NeurogesX, Inc.

    NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

    The Company's lead product, Qutenza®, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza&#
    '/>"/>

    SOURCE NeurogesX
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
    2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
    3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
    4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
    5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
    6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
    7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
    8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
    9. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
    10. NeurogesX to Present at JMP Securities Healthcare Focus Conference
    11. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
    (Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
    (Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led by ... a premier and affordable laser tattoo removal experience with the ... focus is in providing high quality cosmetic services with cutting edge ... " Southern California has seen a dramatic ...
    Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
    ... Connecticut waterways may be safer from biomedical waste, thanks ... program. CEDF, with loan-program partners, Connecticut ,s Department of Economic and Community ... loan to a West Haven company that stems improper disposal of ... , West ...
    ... 14 Hospira, Inc. (NYSE: ... medication delivery company, will expand its commitment to non-DEHP ... of non-DEHP intravenous (I.V.) administration sets. This effort reflects ... and reduced impact on the environment, and coincides with ...
    Cached Medicine Technology:West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund 2Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 2Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 3Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 4
    (Date:4/22/2014)... lung cancer are 70 years of age or older, ... not well represented in clinical trials. Therefore, the paucity ... evidence based clinical recommendations. , In 2010, the EORTC ... Group along with the International Society for Geriatric Oncology ... elderly patients with non-small cell lung cancer (NSCLC), and ...
    (Date:4/22/2014)... to trauma, illness, alcohol or other drug abuse, these ... cells that can go awry and activate conditions such ... autism. , Until now, it has been unclear how ... developing brain. Past studies have shown that when an ... or she experiences some trauma or illness, her baby ...
    (Date:4/22/2014)... (April 22, 2014) Cedars-Sinai stroke intervention researchers have ... and Stroke, part of the National Institutes of Health, ... multicenter Phase II clinical trial of an experimental drug ... used in combination with recombinant tissue plasminogen activator, or ... ischemic strokes shortly after onset. In laboratory rodent studies, ...
    (Date:4/22/2014)... Based on results of a clinical trial ... Food and Drug Administration (FDA) approved a molecularly ... cancer that has progressed after standard chemotherapy has ... review was announced by the manufacturer, Lilly Oncology, ... name ramucirumab, it will be sold under the ...
    (Date:4/22/2014)... of the University of Calgary,s Hotchkiss Brain Institute (HBI) ... cells as a means to restore connections after injury. ... key molecule that directly regulates nerve cell growth in ... the prestigious journal Nature Communications , with lead ... "We made the surprising discovery that a protein called ...
    Breaking Medicine News(10 mins):Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Life stressors trigger neurological disorders, researchers find 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:Scientists discover a new way to enhance nerve growth following injury 2
    ... BELLEVUE, Wash. and WASHINGTON, Oct. 4 Revolution,Health ... fastest growing health,properties, and drugstore.com (Nasdaq: DSCM ... and pharmacy products, today announced a major,agreement whereby ... the Revolution Health Network and manage advertising sales ...
    ... and Research,s (A*STAR) Institute of Molecular and Cell ... provide a more detailed understanding of how the ... albicans transforms into a serious and often life-threatening ... serious and potentially life-threatening infections in the mouth, ...
    ... FAIRFAX, Va., Oct. 4 SRA International, Inc.,(NYSE: ... and strategic consulting,services and solutions to federal government ... an enterprise-wide infrastructure,architecture for the Department of Justice ... Support Services-3 contract, has an,estimated value of $59 ...
    ... ,Tour to Insure, will Highlight Need to Reduce,Costs, Expand ... G.,Rendell will continue his campaign to reduce the costs ... with the passage of the,remainder of his "Prescription for ... bus tour. The five-day, nine-stop "Tour to Insure",will include ...
    ... operational,clinical and technological innovator in emergency medical services, ... ground, this time in the,way it hires the ... and around,Charlotte, N.C. While the nation,s emergency ... already trained in an academic setting,Medic is hiring ...
    ... Drive for Decision, CHARLESTON, S.C., Oct. 4 ... to introduce a proactive self-funding process to,secure the ... for the domestic shrimping industry. Beginning in January ... combination of federal government,assistance, voluntary industry contributions, foundation ...
    Cached Medicine News:Health News:drugstore.com and Revolution Health Group Announce Breakthrough Deal 2Health News:drugstore.com and Revolution Health Group Announce Breakthrough Deal 3Health News:How Candida albicans transforms from its normally benign form into life-threatening form 2Health News:Department of Justice Awards $59M Task Order to SRA 2Health News:Governor Rendell to Fight to 'Cover All Pennsylvanians' During Statewide Bus Tour 2Health News:Mecklenburg EMS Agency Launches Innovative Program to Pay Future EMT's While They Train 2Health News:Wild American Shrimp Board Agrees To Implement New Self-Funding Measures 2
    Full Handle Laseredge Stab Blade Knife, 30 blade. Blade tip dimension: 10.5 mm x 1.9 mm x 3.4 mm....
    19 Gauge. Reusable. Block of 4 each....
    Set consist of two 27 gauge, stainless steel probes with blunt tips. Probes are 11.5 cm (4.5 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto th...
    19 gauge x 8 mm with 15 cm high pressure extension tube preattached to a 10C ring control syringe. 3 per box....
    Medicine Products: